Deep Dive: When Patient Preference Becomes Regulatory Evidence

Patient preference is no longer a soft qualitative afterthought.

What if a device carries significant risks, but patients are willing to accept them for a meaningful clinical benefit?

This Deep Dive examines how FDA’s evolving approach to Patient Preference Information (PPI) can turn those tradeoffs into quantitative evidence for regulatory benefit-risk decisions.

Key highlights covered in the audio:

* PPI is not the same as a patient-reported outcome. PROs describe what patients experience. PPI asks what risks patients are willing to accept to obtain a particular benefit.

* Risk tolerance can be quantified. Methods such as discrete choice experiments and threshold techniques can establish measures such as Maximum Acceptable Risk (MAR) and help define the level of benefit patients consider meaningful.

* Study design matters enormously. Patient comprehension, health numeracy, neutral presentation of risk, attribute selection, statistical analysis plans, and appropriate visual communication can determine whether preference data are credible.

* FDA engagement needs to happen early. The discussion highlights the importance of using the Q-Submission process to align on attributes, ranges, methodology, and statistical analysis before the study is conducted.

* PPI can extend beyond premarket approval. Preference information may inform labeling, shared decision-making, post-market benefit-risk assessments, and other decisions across the total product lifecycle.

Keywords:

Patient Preference Information, FDA Guidance, Benefit-Risk Assessment, Risk Tolerance, Medical Devices, Discrete Choice Experiment, Maximum Acceptable Risk, Q-Submission, Total Product Lifecycle, Risk Management

🎧 Listen to the Deep Dive for a closer look at how patient preference is becoming part of the quantitative language of medical-device risk management.

Thanks for reading Let's Talk Risk!. If you liked this post, share with others.

Note:

The audio summary was prepared using Google NotebookLM, an AI-enabled research tool. Here are a few key resources used for this analysis:

* FDA (2026, March 30). Incorporating Voluntary Patient Preference Information over the Total Product Life Cycle, FDA Guidance Document, U.S. Food and Drug Administration

Pure Global (2026, April 8). FDA 2026 Guidance on Voluntary Patient Preference Information, Strategic Industry Report, Pure Global